Articles related to CME

Hematologist-oncologists, hematology-oncology NP/PAs, hematology-oncology nurses, and pharmacists should be better able to use criteria for erythroid-stimulating agent (ESA) failure to hasten the identification of patients with lower-risk myelodysplastic syndrome (MDS) refractory to ESA therapy, integrate safety and efficacy data on emerging therapeutic options into treatment planning for patients with lower-risk MDS after ESA failure, and integrate a multidisciplinary treatment approach after taking part in this CME activity.

Following completion of this CME activity, health-system and specialty pharmacists should be better able to review the transmissibility and clinical severity associated with SARS-CoV-2 variants, analyze the efficacy of vaccines and boosters for the prevention of infection and severe disease caused by SARS-CoV-2 variants, analyze the efficacy of oral antivirals and remdesivir in light of emerging SARS-CoV-2 variants, and discuss the efficacy of monoclonal antibodies and convalescent plasma for prevention and treatment in the clinical context of current and evolving SARS-CoV-2 variants.

After watching or listening to this CME activity hosted by Cynthia Matossian, MD, FACS, Founder and Medical Director at Matossian Eye Associates in Hopewell, NJ, and Jillian Ziemanski, OD, PhD, FAAO, Clinical Assistant Professor at the UAB School of Optometry at the University of Alabama at Birmingham, ophthalmologists and optometrists should be better equipped to analyze clinical trial data supporting the safety and effectiveness of device therapy to treat meibomian gland dysfunction (MGD).

Participants should be better able to discuss anti-VEGF therapy outcomes in patients with moderate-severe and severe nonproliferative diabetic retinopathy after taking part in this educational activity with Drs. Susan Bressler, Mark Dunbar, and Ruth Weinstock, and understand the importance of prompt referral and early diagnosis to reduce or even prevent the vision-threatening complications of diabetes.

Acquired/congenital bone marrow failure, thalassemia/hemoglobinopathies, transfusion medicine, new therapies (pharmacology), infections of the immunocompromised, hematologic malignancies (acute/chronic leukemias; myeloma/lymphomas), thoracic oncology (head/neck/lung/thyroid), and many other practice improvement areas are covered in this CME activity worth up to 41.25 credits. The video curriculum starts at $1,795 in price.

Approved? Not-approved? What is “tentative approval?” Clinical trial data on this novel “once nightly” sodium oxibate showed the drug to be acceptable for narcolepsy. But legal issues are holding up the FDA approval process.